natgillin/translations-raw huggingface dataset:
This study found that, after treatment for a year, the disease remained stable in 85% of patients treated with Cerdelga compared with 94% of patients who continued with the enzyme replacement therapy.
V študiji so ugotovili, da je po enem letu zdravljenja bolezen ostala stabilna pri 85 % bolnikov, ki so prejemali zdravilo Cerdelga, v primerjavi s 94 % bolnikov, ki so nadaljevali z encimskim nadomestnim zdravljenjem.
This study included 222 patients with relapsed/refractory multiple myeloma, who were randomised in a 2:1 ratio to receive 1.3 mg/m2 of bortezomib by either the subcutaneous or intravenous route for 8 cycles.
V študijo je bilo vključenih 222 bolnikov z relapsom/diseminiranim plazmocitomom, odpornim na zdravljenje, randomiziranih 2:1 na bortezomib, z odmerkom1,3 mg/m2 telesne površine subkutano ali intravensko 8 krogov zdravljenja.
This study included 7 patients with MDS/MPD who were treated with Glivec 400 mg daily.
Ta študija je vključevala 7 bolnikov z MDS/MPD, ki so bili zdravljeni z odmerkom zdravila Glivec 400 mg na dan.
This study included 7 patients with MDS/MPD who were treated with imatinib 400 mg daily.
Ta študija je vključevala 7 bolnikov z MDS/MPD, ki so bili zdravljeni z odmerkom imatiniba 400 mg na dan.
This study included 7 patients with MDS/MPD who were treated with imatinib 400 mg daily.
Ta študija je vključevala 7 bolnikov z MDS/MPD, ki so bili zdravljeni z odmerkom zdravila Imatinib Actavis 400 mg na dan.
This study included patients over 18 years of age with hormone refractory metastatic prostate cancer either measurable by RECIST criteria or non-measurable disease with rising PSA levels or appearance of new lesions, and Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2.
Ta študija je vključila bolnike, starejše od 18 let z metastatskim rakom prostate, odpornim proti hormonom, z merljivo boleznijo po merilih RECIST ali z nemerljivo boleznijo, z naraščanjem koncentracije PSA ali pojavom novih lezij in s stanjem zmogljivosti od 0 do 2 po ECOG (Eastern Cooperative Oncology Group).
This study included subjects who had a LS or FN neck BMD T-score no less than -2.5. The median T-score ranged from -0.6 to -1.4, depending on the skeletal site.
V to študijo so bile vključene osebe, ki so imele oceno T MKG ledvene hrbtenice ali stegneničnega vratu vsaj -2.5. Mediana ocena T je segala od -0,6 do -1,4, odvisno od lokacije v skeletu.
This study investigated the use of combination therapy of MPR (melphalan 0.18 mg/kg orally on days 1-4 of repeated 28-day cycles; prednisone 2 mg/kg orally on days 1-4 of repeated 28-day cycles; and lenalidomide 10 mg/day orally on days 1-21 of repeated 28-day cycles) for induction therapy, up to 9 cycles.
V tej študiji so raziskovali uporabo kombinirane terapije z MPR (melfalan 0,18 mg/kg peroralno od 1. do 4. dne ponavljajočih se 28-dnevnih ciklov; prednizon 2 mg/kg peroralno od 1. do 4. dne ponavljajočih se 28-dnevnih ciklov; in lenalidomid 10 mg/dan peroralno od 1. do 21. dne ponavljajočih se 28-dnevnih ciklov) za indukcijsko zdravljenje, do največ 9 ciklov.
This study is a phase III, randomised, double-blind study of telbivudine 600 mg once daily compared to lamivudine 100 mg once daily for a treatment period of 104 weeks in 332 nucleoside- naïve chronic hepatitis B HBeAg-positive and HBeAg-negative Chinese patients.
Gre za randomizirano, dvojno slepo študijo faze III, v kateri so primerjali telbivudin 600 mg enkrat na dan z lamivudinom 100 mg enkrat na dan v 104-tedenskem obdobju zdravljenja pri 332 HBeAg-pozitivnih in HBeAg-negativnih kitajskih bolnikih s kroničnim hepatitisom B, ki še niso prejemali nukleozidnega zdravljenja.
This study is being done in patients with oestrogen-receptor positive breast cancer that has spread or progressed after previous treatment with letrozole or anastrozole.
Študija se izvaja pri bolnikih z rakom dojke, pozitivnim na estrogenske receptorje, ki se je razširil ali napredoval po predhodnem zdravljenju z letrozolom ali anastrozolom.
This study lasted 13 weeks and looked at the proportion of patients whose platelet count had increased to at least 50,000 cells per microlitre for at least 6 out of 8 weeks, between week 5 to 12 of the study in the absence of rescue medication.
V študiji, ki je trajala 13 tednov, so proučevali delež bolnikov, pri katerih se je število trombocitov povečalo za vsaj 50 000 celic na mikroliter v najmanj šestih tednih od osmih med petim in dvanajstim tednom študije brez olajševalnega zdravila.
This study looked at how many patients had developed an illness associated with AIDS or had died after a year’s treatment.
V tej študiji so proučevali, pri koliko bolnikih se je razvila bolezen, povezana z aidsom, ali koliko jih je umrlo po enoletnem zdravljenju.
This study looked at how well the treatments reduced the time when patients have more difficulty moving about, called ‘off periods’.
V tej študiji so preučevali, kako učinkoviti sta bili zdravili pri zmanjševanju časa, ko so imeli bolniki več težav z gibanjem – ta pojav imenujemo „obdobja izklopa“.
This study looked at how well the treatments reduced the time when patients have more difficulty moving about, called ‘off periods’.
V tej študiji so proučevali, kako učinkovito so zdravila skrajšala čas, ko so imeli bolniki več težav z gibanjem – „čas izklopa“.
This study looked at the ability of the vaccine when injected under the skin, to trigger the production of antibodies against the viruses (‘immunogenicity’).
V tej študiji so proučevali zmožnost cepiva, da sproži tvorbo protiteles proti virusom (imunogenost), če je injicirano pod kožo.
This study looked at the blood levels of the enzyme lactate dehydrogenase (LDH), which reflect the extent of the breakdown of red blood cells.
V njej so proučevali ravni encima laktatna dehidrogenaza (LDH) v krvi, kar je pokazatelj obsega razgradnje rdečih krvnih celic.
This study looked at viral load after 24 and 48 weeks.
V tej študiji so proučevali virusno breme po 24 in 48 tednih.
This study showed an increase in reports of heart failure, however this did not lead to an increase in mortality in this study.
Študija je pokazala povečano število poročil o srčnem popuščanju, vendar pa v tej študiji to ni povzročilo povečane smrtnosti.
This study showed an increase in reports of heart failure, however this did not lead to an increase in mortality in this study..
Ta študija je pokazala povečanje poročil srčnega popuščanja, vendar to ni vodilo k dvigu smrtnosti v tej študiji.
This study showed that the dogs receiving meloxicam injection followed by oral doses had the highest score of excellent/good.
Ta študija je pokazala, da so imeli psi, ki so prejeli injekcijo meloksikama, ki ji je sledilo peroralno jemanje zdravila, največkrat oceno odlično/dobro.
This study supports 500 μg once every three weeks being comparable to once weekly administration with respect to the incidence of subjects receiving at least one red blood cell transfusion from week 5 to the end of treatment phase.
Študija potrjuje, da je uporaba 500 µg enkrat na tri tedne primerljiva uporabi enkrat na teden, kar zadeva incidenco preiskovancev, ki so od 5. tedna do konca faze zdravljenja dobili vsaj eno transfuzijo eritrocitov.
This study was an open-label, randomised, active-controlled (sevelamer carbonate), parallel group study for up to 55 weeks.
To je bila odprta, randomizirana, z zdravilno učinkovino kontrolirana (sevelamerijev karbonat), vzporedna skupinska študija, ki je trajala do 55 tednov.
This study was conducted in the presence of another two direct-acting antiviral agents.
Ta študija je bila opravljena v prisotnosti dveh drugih učinkovin z direktnim delovanjem na viruse.
This study was extended to look at the effects of giving a booster dose of Bexsero at or after 12 months of age to children who had already received Bexsero in early infancy, compared with giving two ‘catch-up’ doses to those who had not.
Študija je bila razširjena tako, da je proučevala učinke dajanja poživitvenega odmerka cepiva Bexsero otrokom pri starosti 12 mesecev ali po dopolnjenih 12 mesecih, ki so to cepivo že prejeli kot dojenčki, v primerjavi z dajanjem dveh naknadnih odmerkov otrokom, ki cepiva prej niso prejeli.
This substance may be harmful for people with phenylketonuria (a metabolic disease).
Ta snov lahko škoduje ljudem s fenilketonurijo (presnovna bolezen).
This suggests that bortezomib distributes widely to peripheral tissues.
To nakazuje, da se bortezomib v veliki meri porazdeljuje v periferna tkiva.
This suggests that imaging can be accomplished anytime between one and eight hours after injection (at the convenience of the nuclear medicine department and the patient).
To dejstvo pove, da je preiskava lahko izvršena kadarkoli v časovnem obdobju ene do osmih ur po injiciranju (tako, da je najugodneje za oddelek nuklearne medicine in za bolnika).
This summary was last updated in 01-2007.
Ta povzetek je bil nazadnje posodobljen 01-2007.
This summary was last updated in 01-2015.
Povzetek je bil nazadnje posodobljen 01-2016.
This summary was last updated in 01-2016.
EMA/796393/2015 stran 2/2
This summary was last updated in 01-2016.
Odstranjevanje
This summary was last updated in 02-2007.
Ta povzetek je bil nazadnje posodobljen 02-2007.
This summary was last updated in 03-2007.
Povzetek je bil nazadnje posodobljen 03-2007.
This summary was last updated in 03-2008.
Povzetek je bil nazadnje posodobljen 03-2008.
This summary was last updated in 03-2014
Ta povzetek je bil nazadnje posodobljen 03-2014.
This summary was last updated in 03-2014.
Povzetek je bil nazadnje posodobljen 01-2016.
This summary was last updated in 04-2007.
Povzetek je bil nazadnje posodobljen 04-2007.
This summary was last updated in 05/2013.
Povzetek je bil nazadnje posodobljen 05/2013.
This summary was last updated in 05/2014.
Povzetek je bil nazadnje posodobljen 05/2014.
This summary was last updated in 07-2016.
Povzetek je bil nazadnje posodobljen 08/2012.
This summary was last updated in 08-2006
Ta povzetek je bil nazadnje posodobljen 08-2006.
This summary was last updated in 09-2016.
EMA/CHMP/517539/2016 stran 2/2
This summary was last updated in 09-2016.
Povzetek je bil nazadnje posodobljen 08-2016.
This summary was last updated in 1-2006
Ta povzetek je bil nazadnje posodobljen 1-2006.
This summary was last updated in 10-2006.
Ta povzetek je bil nazadnje posodobljen 10-2006.
This summary was last updated in 10-2011.
Povzetek je bil nazadnje posodobljen 10–2011.
This summary was last updated in 11-2011.
Povzetek je bil nazadnje posodobljen 11 – 2011.
This summary was last updated in 11-2011.
Povzetek je bil nazadnje posodobljen 11–2011.
This summary was last updated in 11-2014
Povzetek je bil nazadnje posodobljen 11-2014.
This summary was last updated in 12-2011.
Povzetek je bil nazadnje posodobljen 12–2011.
This summary was last updated in 12-2015.
EMA/635371/2015 stran 2/2
This summary was last updated in 9-2015.
Povzetek je bil nazadnje posodobljen 09-2015.
This summary was last updated in April 2014.
Povzetek je bil nazadnje posodobljen aprila 2014.
This summary was last updated in December 2015.
Povzetek je bil nazadnje posodobljen decembra 2015.
This summary was last updated in January 2013.
Povzetek je bil nazadnje posodobljen januarja 2013.
This summary was last updated in July 2016.
Povzetek je bil nazadnje posodobljen julija 2016.
This summary was last updated in June 2013
Povzetek je bil nazadnje posodobljen junija 2013.
This summary was last updated in May 2013.
Ta povzetek je bil nazadnje posodobljen 5-2013.
This summary was last updated in September 2014.
Povzetek je bil nazadnje posodobljen septembra 2014.
This summary was last updated on 03/09/2012.
Povzetek je bil nazadnje posodobljen 3.
This summary was last updated on 09/01/2012.
Ta povzetek je bil nazadnje posodobljen dne 09/01/2012.
This summary was last updated on 13 February 2008.
Ta povzetek je bil nazadnje posodobljen 13. februarja 2008.
This summary was last updated on 13 February 2013.
Povzetek je bil nazadnje posodobljen dne 13.02.2013.
This summary was last updated on 16 July 2012.
Povzetek je bil nazadnje posodobljen 16.
This summary was last updated on 17 June 2009.
Povzetek je bil nazadnje posodobljen 17. junija 2009.
This summary was last updated on 25 February 2013.
Povzetek je bil nazadnje posodobljen 25/02/2013.
This summary was last updated on 25 June 2009.
Povzetek je bil nazadnje posodobljen 25. junija 2009.
This summary was last updated: 21/02/2011
Povzetek je bil nazadnje posodobljen 21/02/2011
This swelling normally resolves within 1 to 5 days.
Ta oteklina navadno izgine v 1 do 5 dni.
This swelling resolves completely within 3 weeks and normally has no effect on the appetite of the vaccinated animal and causes no apparent discomfort.
V 3 tednih povsem mine in običajno ne vpliva na apetit cepljene živali niti ne povzroča vidnega nelagodja.
This syringe can only be used for one single injection, and must be thrown away after use.
Brizgo je mogoče uporabiti le za eno injiciranje in jo je treba po uporabi zavreči.
This system generates droplets by ultrasound, which forces the solution through a mesh.
Nebulatorski sistem z ultrazvokom potiska raztopino skozi mrežico in tako ustvarja kapljice.
This system generates droplets by ultrasound, which is forcing the solution through a mesh.
Nebulatorski sistem z ultrazvokom potiska raztopino skozi mrežico in tako ustvarja kapljice.
this table for futher information
v tej preglednici.
This table provides the amount of solvent required to reconstitute ZYPADHERA powder for prolonged release suspension for injection.
Ta tabela podaja količino vehikla potrebnega za rekonstitucijo ZYPADHERA praška za suspenzijo za injiciranje s podaljšanim sproščanjem.
This takes about 30 minutes.
To traja približno 30 minut.
This tells you that the medicine is being injected.
To vam pove, da injiciranje zdravila poteka.
This test should not affect your ability to drive or use machines.
Ta test ne bo vplival na vašo sposobnost upravljanja vozil in strojev.
This therefore boosts atazanavir’s antiviral effect.
To okrepi protivirusni učinek atazanavirja.
This therefore boosts trifluridine’s effect.
To okrepi učinek trifluridina.
This time-to- event endpoint is strongly affected by the high crossover rate from IFN+Ara-C to imatinib.
Na ta opazovani dogodek, ki se veže na čas do dogodka, je močno vplival velik delež bolnikov, ki so z zdravljenja z IFN+Ara-C prešli na imatinib.
This total dose can be given either as an injection of 1 mg/kg asfotase alfa 6 times per week or as 2 mg/kg asfotase alfa 3 times per week depending on the recommendation of your doctor.
Ta skupni odmerek se da kot injekcija 1 mg/kg asfotaze alfa 6-krat na teden ali kot 2 mg/kg asfotaze alfa 3-krat na teden, odvisno od priporočila zdravnika.
This transient effect may be explained by the fact that protein C, itself a vitamin K dependent plasma protein, has a shorter half-life than most of the vitamin K dependent proteins (i.e.
Ta prehodni učinek lahko razložimo z dejstvom, da ima protein C, ki je tudi od vitamina K odvisen plazemski protein, krajšo razpolovno dobo od večine proteinov, odvisnih od vitamina K (npr.
This translates into an absolute benefit in terms of an 8 year disease free survival rate of 6.4 percentage points in favour of 1 year Herceptin treatment.
To se izraža kot absolutna korist enoletnega zdravljenja z zdravilom Herceptin v smislu 8-letnega preživetja brez bolezni za 6,4 odstotne točke.
This treatment cycle will normally be repeated every three weeks.
Ta cikel zdravljenja se običajno ponovi vsake tri tedne.
This treatment effect was comparable to that of insulin glargine in a 26-week study (mean insulin dose 24.9 IU/day, range 4-95 IU/day, at the end of study) and biphasic insulin aspart in a 52-week study (mean insulin dose 24.4 IU/day, range 3-78 IU/day, at the end of study).
Ta učinek zdravljenja je bil primerljiv z učinkom insulina glargin v 26-tedenski študiji (povprečni odmerek insulina 24,9 i.e./dan, razpon 4-95 i.e./dan, ob koncu študije) in dvofaznega insulina aspart v 52- tedenski študiji (povprečni odmerek insulina 24,4 i.e./dan, razpon 3-78 i.e./dan, ob koncu študije).
This treatment may vary, depending on the results of your regular blood tests.
Zdravljenje je lahko tudi drugačno, odvisno od izvidov rednih krvnih preiskav.
This treatment schedule is repeated every 21 days for 6 courses or until progressive disease.
To shemo zdravljenja ponavljajte na vsakih 21 dni 6 ciklusov ali dokler bolezen ne napreduje.
This treatment schedule is repeated every 21 days for six courses or until progressive disease.
Takšna shema zdravljenja se ponavlja vsakih 21 dni, šest ciklov ali dokler bolezen ne napreduje.
This trend was not observed in the PsA population.
Takšne tendence niso opazili v skupini bolnikov s
This trial compared the efficacy and safety of Faslodex 500 mg (n=362) with Faslodex 250 mg (n=374).
To preskušanje je primerjalo učinkovitost in varnost zdravila Faslodex 500 mg (n = 362) in zdravila Faslodex 250 mg (n = 374).
This turns the solution to foam that can’t be drawn into the syringe.
Raztopina se lahko spremeni v peno, ki je ni možno posrkati v injekcijsko brizgo.
This type of cancer has usually resulted in death.
Ta vrsta raka se je ponavadi končala s smrtnim izidom.
This type of medicine is called “chemo-therapy”.
Ta tip zdravljenja se imenuje kemoterapija.
This type of transplant is used in patients who need to replace their blood-making cells because they have a blood disease such as a cancer of the blood (including leukaemia) or diseases causing low red blood cell counts (including thalassaemia or sickle-cell anaemia); during the treatment of solid tumours when high-dose chemotherapy followed by transplantation of haematopoietic progenitor cells is needed.
Ta vrsta presaditve se uporablja pri bolnikih, pri katerih je treba zamenjati krvotvorne celice, ker imajo krvno bolezen, kot je krvni rak (vključno z levkemijo), ali bolezen, ki povzroča nizko raven rdečih krvničk (vključno s talasemijo ali anemijo srpastih celic); med zdravljenjem čvrstih tumorjev, ko je potrebna kemoterapija z visokimi odmerki, kateri sledi presaditev krvotvornih matičnih celic.
This type of treatment is called ‘immunomodulation’ (immune adjustment).
Ta vrsta zdravljenja se imenuje „imunomodulacija“ (spreminjanje imunske odzivnosti);
This type usually starts when you are young and your body does not produce any insulin. if you experience rapid weight loss, feeling sick or being sick, stomach pain, excessive thirst, fast and deep breathing, confusion, unusual sleepiness or tiredness, a sweet smell to your breath, a sweet or metallic taste in your mouth or a different odour to your urine or sweat, contact a doctor or the nearest hospital straight away.
Ta tip se običajno pojavi v mladih letih in ko telo insulina ne proizvaja več. če pride do hitre izgube telesne mase, občutka slabosti ali bruhanja, bolečin v želodcu, prekomerne žeje, hitrega in globokega dihanja, zmedenosti, neobičajne zaspanosti ali utrujenosti, sladkastega zadaha, sladkega ali kovinskega okusa v ustih ali drugačnega vonja urina ali znoja, se nemudoma posvetujte z zdravnikom ali pojdite v najbližjo bolnišnico.
This upsets the essential functions that keep the cell alive, and kills the bacteria.
S tem prekine ključne funkcije, ki ohranjajo celico živo, in uniči bakterijo.
This usually means one capsule at breakfast, lunch and dinner.
Po navadi to pomeni po eno kapsulo pri zajtrku, kosilu in večerji.
This usually means one tablet at breakfast, lunch and dinner.
Po navadi to pomeni po eno tableto pri zajtrku, kosilu in večerji.
This usually resolves on its own within three to four weeks.
Običajno izginejo sami od sebe v treh do štirih tednih.
This usually stops after the first few cycles.
Te ponavadi prenehajo po prvih nekaj ciklih.
This vaccine can be administered: with hepatitis B immunoglobulin, at a separate injection site. to complete a primary immunisation course or as a booster dose in subjects who have previously received another hepatitis B vaccine. concomitantly with other vaccines, using separate sites and syringes.
Cepivo je mogoče uporabiti: z imunoglobulinom proti hepatitisu B, a na drugem vbodnem mestu, za dokončanje primarnega niza cepljenja ali kot obnovitveni odmerek pri osebah, ki so prej dobile drugo cepivo proti hepatitisu B, hkrati z drugimi cepivi, vendar v drugi brizgi in na drugem vbodnem mestu.
This vaccine can be used during pregnancy and lactation.
Lahko se uporablja v obdobju brejosti in laktacije.
This vaccine complies with the WHO (World Health Organisation) recommendations (Northern Hemisphere) and EU decision for the 2016/2017 season.
Cepivo ustreza priporočilom SZO (Svetovne zdravstvene organizacije) (severna polobla) in odločbi EU za sezono 2016/2017.
This vaccine complies with the WHO recommendation (Northern Hemisphere) and EU decision for the 2013/2014 season.
Cepivo ustreza priporočilom Svetovne zdravstvene organizacije (severna polobla) in odločbi EU za sezono 2013/2014.
This vaccine complies with the WHO recommendation (Northern Hemisphere) and EU decision for the 2016/2017 season.
Cepivo ustreza priporočilom Svetovne zdravstvene organizacije (severna polobla) in odločbi EU za sezono 2016/2017.
This vaccine complies with the WHO recommendations (Northern Hemisphere) and EU decision for the 2016/2017 season.
Cepivo ustreza priporočilom Svetovne zdravstvene organizacije (severna polobla) in Odločbi EU za sezono 2016/2017.
This vaccine complies with the WHO recommendations (Northern Hemisphere) and EU decision for the 2016/2017 season.
Cepivo ustreza priporočilom SZO (Svetovne zdravstvene organizacije) (severna polobla) in odločbi EU za sezono 2016/2017.
This vaccine contains 1080 mg sucrose (see section 4.4).
Cepivo vsebuje 1080 mg saharoze (glejte poglavje 4.4).
This vaccine contains 14.5 mg of sorbitol as an excipient.
Cepivo kot pomožno snov vsebuje 14,5 mg sorbitola.
This vaccine contains 16 mg of sorbitol as an excipient.
To cepivo vsebuje kot pomožno snov 16 mg sorbitola.
This vaccine contains less than 1 mmol sodium (23 mg) per dose, i.e. essentially ‘sodium-free’.
To cepivo vsebuje manj kot 1 mmol (23 mg) natrija na odmerek, kar v bistvu pomeni ‘brez natrija’.
This vaccine contains neomycin and polymyxin (antibiotics).
To cepivo vsebuje neomicin ali polimiksin (antibiotika).
This vaccine contains neomycin and polymyxin (antibiotics).
To cepivo vsebuje neomicin in polimiksin (antibiotika).
This vaccine contains potassium, less than 1 mmol (39 mg) per dose, i.e. essentially ‘potassium-free’.
To cepivo vsebuje manj kot 1 mmol (39 mg) kalija na odmerek, kar v bistvu pomeni ‘brez kalija’.
This vaccine contains thiomersal as a preservative and it is possible that you may experience an allergic reaction.
To cepivo vsebuje kot konzervans tiomersal, ki lahko povzroči alergijsko reakcijo.
This vaccine does not protect against infections caused by other types of Haemophilus influenzae nor against meningitis due to other micro-organisms.
Cepivo ne ščiti pred okužbami, ki jih povzročajo drugi tipi Haemophilusa influenzae, ali pred meningitisom, ki ga povzročajo drugi mikroorganizmi.
This vaccine has been prescribed for you or your child only.
Cepivo je bilo predpisano vam ali vašemu otroku osebno.
This vaccine has been prescribed for you or your child only.
Cepivo je bilo predpisano vam osebno ali vašemu otroku.
This vaccine has been prescribed for you or your child only.
To cepivo je bilo predpisano vam ali vašemu otroku osebno in ga ne smete dajati drugim.
This vaccine has been prescribed for your child and you should not pass it on to others.
Cepivo je bilo predpisano vašemu otroku in ga ne smete dajati drugim.
This vaccine has been tested for safety in chickens. and some supportive data for safety in ducks are available.
Varnost cepiva je testirana pri piščancih, o njegovi varnosti pri racah pa je na voljo nekaj spremljajočih podatkov.
This vaccine has no or negligible influence on the ability to drive and use machines.
Cepivo IDflu nima oziroma zanemarljivo vpliva na sposobnost vožnje in upravljanja s stroji.
This vaccine has no or negligible influence on the ability to drive and use machines.
Cepivo INTANZA nima oziroma zanemarljivo vpliva na sposobnost vožnje in upravljanja s stroji.